IL-12 was also engineered to be expressed by oncolytic MeV (MeVac FmIL-12), which led to complete remission in 90% of MC38 tumor models.216 Enhanced therapeutic efficacy was realized by activation of the systemic antitumor immune response through increased expression of inflammatory cytokines (IFN-γ, TNF-α, and IL-6).217. Here, IL6 is linked to neoplasm.